955029-44-4

Basic information

• Product Name: 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate
• Synonyms: 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate;tert-Butyl-(3R,4R)-3-fluoro-4-hydroxy-piperidine-1-carboxylate;trans-1-boc-3-fluoro-4-hydroxypiperidine;tert-butyl (3.4)-trans-3-fluoro-4-hydroxypiperidine-1-carboxylate racemate;tert-butyl trans-3-fluoro-4-hydroxypiperidine-1-carboxylate
• CAS NO: 955029-44-4
• Molecular Formula: C10H18FNO3
• Molecular Weight: 219.26
• EINECS: -0
• Mol File: 955029-44-4.mol

Chemical Properties

• Boiling Point: 300.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.65±0.40(Predicted)
• CAS DataBase Reference: 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate(955029-44-4)
• EPA Substance Registry System: 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate(955029-44-4)

Safety Data

• Hazardous Substances Data: 955029-44-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structural features, including the fluoro and hydroxy groups, make it a versatile building block for the synthesis of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate is used as a starting material for the development of new drugs, particularly in the field of medicinal chemistry. Its potential applications include the synthesis of biologically active compounds with therapeutic properties, such as antimicrobial, antiviral, and anticancer agents.
Used in Drug Development:
The presence of the fluoro and hydroxy groups in the molecule of 2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate makes it a promising candidate for the development of new drugs. These functional groups can be further modified or used as a basis for the synthesis of more complex molecules with improved pharmacological properties.
Used in Medicinal Chemistry:
2)Trans-tert-butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate is utilized in medicinal chemistry for the design and synthesis of novel drug candidates. Its unique structural features and reactivity make it a valuable tool for the development of new therapeutic agents with improved efficacy and selectivity.

Upstream product

• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 913574-95-5 trans benzyl 3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 1208864-35-0 tert-butyl 3-fluoro-4,4-dihydroxypiperidin-1-carboxylic acid 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 161157-50-2 tert-butyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 845256-59-9 benzyl 3-fluoro-4-oxopiperidine-1-carboxylate 
• 1147998-34-2 phenylmethyl 4-[(trimethylsilyl)oxy]-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 913574-95-5 benzyl trans-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 913574-95-5 benzyl cis-3-fluoro-4-hydroxypiperidine-1-carboxylate 
• 22282-73-1 3-fluoropyridin-4-ol 

Relevant articles and documents

Efforts towards a Noyori reduction of a 3-fluorpiperidin-4-one with dynamic kinetic resolution

A Noyori reduction of racemic 1-Boc-3-fluoropiperidin-4-one has been achieved under dynamic kinetic resolution conditions that results in a single cis enantiomer being obtained with both diastereo- and enantioselectivity > 90%. This medicinal chemistry building block can be generated on multi-gram scale using the developed conditions to a single enantiomer in a 60% yield after employing a crystallisation procedure.

6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS

The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

PYRIMIDINE PYRAZOLYL DERIVATIVES

The present invention provides compounds of Formula (I) for the treatment of cancer, rheumatoid arthritis and other diseases (I).